145 search results for STAT3
| # | SuperPathway Name | Genes Count | Relevance Score | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ncRNAs involved in STAT3 signaling in hepatocellular carcinoma | 18 | 1.690 | |||||||
|
||||||||||
| 2 | Regulatory circuits of the STAT3 signaling pathway | 24 | 1.690 | |||||||
|
||||||||||
| 3 | Hepatocyte growth factor receptor signaling | 115 | 0.961 | |||||||
|
||||||||||
| 4 | MIF Mediated Glucocorticoid Regulation | 681 | 0.961 | |||||||
|
||||||||||
| 5 | Serotonin HTR1 group and FOS pathway | 42 | 0.961 | |||||||
|
||||||||||
| 6 | Neurotrophic factor-mediated Trk receptor signaling | 50 | 0.961 | |||||||
|
||||||||||
| 7 | Signaling by PTK6 | 54 | 0.961 | |||||||
|
||||||||||
| 8 | Signaling by ALK | 27 | 0.961 | |||||||
|
||||||||||
| 9 | Transcriptional Regulatory Network in Embryonic Stem Cell | 42 | 0.341 | |||||||
|
||||||||||
| 10 | Acute myeloid leukemia | 66 | 0.341 | |||||||
|
||||||||||
| 11 | PDGFR-beta signaling pathway | 146 | 0.341 | |||||||
|
||||||||||
| 12 | Programmed Cell Death | 213 | 0.341 | |||||||
|
||||||||||
| 13 | Transcriptional regulation of pluripotent stem cells | 24 | 0.341 | |||||||
|
||||||||||
| 14 | TCR Signaling (Qiagen) | 238 | 0.341 | |||||||
|
||||||||||
| 15 | Development VEGF signaling via VEGFR2 - generic cascades | 147 | 0.341 | |||||||
|
||||||||||
| 16 | Gastrin signaling pathway | 112 | 0.341 | |||||||
|
||||||||||
| 17 | IL2 signaling events mediated by STAT5 | 74 | 0.341 | |||||||
|
||||||||||
| 18 | Signaling events mediated by HDAC Class I | 118 | 0.341 | |||||||
|
||||||||||
| 19 | Interleukin-7 signaling | 36 | 0.341 | |||||||
|
||||||||||
| 20 | Autophagy in pancreatic ductal adenocarcinoma | 20 | 0.341 | |||||||
|
||||||||||
| 21 | Signaling by CSF3 (G-CSF) | 30 | 0.341 | |||||||
|
||||||||||
| 22 | Embryonic and Induced Pluripotent Stem Cells and Lineage-specific Markers | 133 | 0.341 | |||||||
|
||||||||||
| 23 | Clear cell renal cell carcinoma pathways | 85 | 0.341 | |||||||
|
||||||||||
| 24 | ErbB2/ErbB3 signaling events | 32 | 0.341 | |||||||
|
||||||||||
| 25 | Microtubule cytoskeleton regulation | 46 | 0.341 | |||||||
|
||||||||||
| 26 | Akt Signaling | 682 | 0.341 | |||||||
|
||||||||||
| 27 | Signaling by Receptor Tyrosine Kinases | 524 | 0.341 | |||||||
|
||||||||||
| 28 | Acute viral myocarditis | 75 | 0.341 | |||||||
|
||||||||||
| 29 | Breast cancer pathway | 199 | 0.341 | |||||||
|
||||||||||
| 30 | Cancer immunotherapy by PD-1 blockade | 23 | 0.341 | |||||||
|
||||||||||
| 31 | Interleukin-37 signaling | 21 | 0.341 | |||||||
|
||||||||||
| 32 | NF-kappaB Signaling | 327 | 0.341 | |||||||
|
||||||||||
| 33 | FGFR1 mutant receptor activation | 38 | 0.341 | |||||||
|
||||||||||
| 34 | CCL18 signaling pathway | 96 | 0.341 | |||||||
|
||||||||||
| 35 | IL-10 Pathway | 35 | 0.341 | |||||||
|
||||||||||
| 36 | FGF signaling pathway | 54 | 0.341 | |||||||
|
||||||||||
| 37 | Leptin-insulin signaling overlap | 21 | 0.341 | |||||||
|
||||||||||
| 38 | Integrin-mediated cell adhesion | 140 | 0.341 | |||||||
|
||||||||||
| 39 | Immune response_IL-6 signaling pathway | 33 | 0.341 | |||||||
|
||||||||||
| 40 | Signaling events mediated by TCPTP | 39 | 0.341 | |||||||
|
||||||||||
| 41 | Interactions between immune cells and microRNAs in tumor microenvironment | 48 | 0.341 | |||||||
|
||||||||||
| 42 | JAK-STAT signaling in the regulation of Beta-cells | 35 | 0.341 | |||||||
|
||||||||||
| 43 | Endometrial cancer | 201 | 0.341 | |||||||
|
||||||||||
| 44 | Nuclear receptors meta-pathway | 315 | 0.341 | |||||||
|
||||||||||
| 45 | Interleukin-1 family signaling | 153 | 0.341 | |||||||
|
||||||||||
| 46 | Cellular responses to stimuli | 802 | 0.341 | |||||||
|
||||||||||
| 47 | fMLP Pathway | 266 | 0.341 | |||||||
|
||||||||||
| 48 | IL27-mediated signaling events | 60 | 0.341 | |||||||
|
||||||||||
| 49 | CCR5 Pathway in Macrophages | 321 | 0.341 | |||||||
|
||||||||||
| 50 | MAPK-Erk Pathway | 275 | 0.341 | |||||||
|
||||||||||
| 51 | Th17 Differentiation | 62 | 0.341 | |||||||
|
||||||||||
| 52 | ERK Signaling | 1185 | 0.341 | |||||||
|
||||||||||
| 53 | IL12-mediated signaling events | 85 | 0.341 | |||||||
|
||||||||||
| 54 | Dopaminergic neurogenesis | 30 | 0.341 | |||||||
|
||||||||||
| 55 | Adipogenesis | 131 | 0.341 | |||||||
|
||||||||||
| 56 | Crizotinib Pathway, Pharmacokinetics/Pharmacodynamics | 38 | 0.341 | |||||||
|
||||||||||
| 57 | p70S6K Signaling | 392 | 0.341 | |||||||
|
||||||||||
| 58 | Development EGFR signaling pathway | 154 | 0.341 | |||||||
|
||||||||||
| 59 | MicroRNAs in cardiomyocyte hypertrophy | 112 | 0.341 | |||||||
|
||||||||||
| 60 | Signaling by FGFR2 in disease | 63 | 0.341 | |||||||
|
||||||||||
| 61 | Signaling by PDGF | 58 | 0.341 | |||||||
|
||||||||||
| 62 | G-protein signaling RAC1 in cellular process | 108 | 0.341 | |||||||
|
||||||||||
| 63 | IL12 signaling mediated by STAT4 | 27 | 0.341 | |||||||
|
||||||||||
| 64 | Development Dopamine D2 receptor transactivation of EGFR | 128 | 0.341 | |||||||
|
||||||||||
| 65 | TGF-beta receptor signaling in skeletal dysplasias | 59 | 0.341 | |||||||
|
||||||||||
| 66 | MET promotes cell motility | 118 | 0.341 | |||||||
|
||||||||||
| 67 | Neuroinflammation and glutamatergic signaling | 140 | 0.341 | |||||||
|
||||||||||
| 68 | Thyroid stimulating hormone (TSH) signaling pathway | 58 | 0.341 | |||||||
|
||||||||||
| 69 | Interleukin-11 signaling pathway | 44 | 0.341 | |||||||
|
||||||||||
| 70 | IL-10 anti-inflammatory signaling pathway | 4 | 0.341 | |||||||
|
||||||||||
| 71 | Immune response IL-23 signaling pathway | 160 | 0.341 | |||||||
|
||||||||||
| 72 | Cytoskeleton remodeling Role of PDGFs in cell migration | 40 | 0.341 | |||||||
|
||||||||||
| 73 | Growth hormone receptor signaling | 29 | 0.341 | |||||||
|
||||||||||
| 74 | Prolactin Signaling | 432 | 0.341 | |||||||
|
||||||||||
| 75 | Interleukin-6 family signaling | 33 | 0.341 | |||||||
|
||||||||||
| 76 | TGF-Beta Pathway | 653 | 0.341 | |||||||
|
||||||||||
| 77 | MAPK Pathway | 88 | 0.341 | |||||||
|
||||||||||
| 78 | Interleukin-12 family signaling | 57 | 0.341 | |||||||
|
||||||||||
| 79 | Overview of interferons-mediated signaling pathway | 168 | 0.341 | |||||||
|
||||||||||
| 80 | Inflammatory bowel disease signaling | 43 | 0.341 | |||||||
|
||||||||||
| 81 | GPCR Pathway | 712 | 0.341 | |||||||
|
||||||||||
| 82 | Development of pulmonary dendritic cells and macrophage subsets | 13 | 0.341 | |||||||
|
||||||||||
| 83 | Busulfan Pathway, Pharmacodynamics | 36 | 0.341 | |||||||
|
||||||||||
| 84 | IL 10 signaling pathway | 62 | 0.341 | |||||||
|
||||||||||
| 85 | mBDNF and proBDNF regulation of GABA neurotransmission | 38 | 0.341 | |||||||
|
||||||||||
| 86 | Immune response_IL-12 signaling pathway | 25 | 0.341 | |||||||
|
||||||||||
| 87 | G-protein signaling G-Protein alpha-i signaling cascades | 210 | 0.341 | |||||||
|
||||||||||
| 88 | Metabolism of proteins | 1970 | 0.341 | |||||||
|
||||||||||
| 89 | Signaling by SCF-KIT | 43 | 0.341 | |||||||
|
||||||||||
| 90 | Signaling by NTRKs | 134 | 0.341 | |||||||
|
||||||||||
| 91 | Development EPO-induced Jak-STAT pathway | 75 | 0.341 | |||||||
|
||||||||||
| 92 | NFAT and Cardiac Hypertrophy | 326 | 0.341 | |||||||
|
||||||||||
| 93 | Cellular Senescence | 196 | 0.341 | |||||||
|
||||||||||
| 94 | IL-17 Family Signaling Pathways | 108 | 0.341 | |||||||
|
||||||||||
| 95 | Integrin Pathway | 570 | 0.341 | |||||||
|
||||||||||
| 96 | Prion disease pathway | 32 | 0.341 | |||||||
|
||||||||||
| 97 | Nuclear events mediated by NFE2L2 | 199 | 0.341 | |||||||
|
||||||||||
| 98 | Cytokine Signaling in Immune system | 732 | 0.341 | |||||||
|
||||||||||
| 99 | Development A3 receptor signaling | 106 | 0.341 | |||||||
|
||||||||||
| 100 | Neural crest cell migration in cancer | 34 | 0.341 | |||||||
|
||||||||||
| 101 | Chaperonin-mediated protein folding | 97 | 0.341 | |||||||
|
||||||||||
| 102 | Neurogenesis regulation in the olfactory epithelium | 57 | 0.341 | |||||||
|
||||||||||
| 103 | DREAM Repression and Dynorphin Expression | 250 | 0.341 | |||||||
|
||||||||||
| 104 | Signaling by PDGFR in disease | 20 | 0.341 | |||||||
|
||||||||||
| 105 | CNTF Signaling | 149 | 0.341 | |||||||
|
||||||||||
| 106 | Transcription factors regulate miRNAs related to cardiac hypertrophy | 9 | 0.341 | |||||||
|
||||||||||
| 107 | IL-9 Signaling Pathways | 169 | 0.341 | |||||||
|
||||||||||
| 108 | Interleukin-4 and Interleukin-13 signaling | 108 | 0.341 | |||||||
|
||||||||||
| 109 | Estrogen receptor pathway | 13 | 0.341 | |||||||
|
||||||||||
| 110 | Interleukin-2 family signaling | 72 | 0.341 | |||||||
|
||||||||||
| 111 | IL3-mediated signaling events | 43 | 0.341 | |||||||
|
||||||||||
| 112 | Nervous system development | 1168 | 0.341 | |||||||
|
||||||||||
| 113 | Signaling events mediated by PTP1B | 46 | 0.341 | |||||||
|
||||||||||
| 114 | Jak-Stat Signaling Pathway | 88 | 0.341 | |||||||
|
||||||||||
| 115 | Urotensin-II-mediated signaling pathway | 45 | 0.341 | |||||||
|
||||||||||
| 116 | Th17 cell differentiation pathway | 69 | 0.341 | |||||||
|
||||||||||
| 117 | Interleukin-20 family signaling | 25 | 0.341 | |||||||
|
||||||||||
| 118 | IL6-mediated signaling events | 45 | 0.341 | |||||||
|
||||||||||
| 119 | IL-26 signaling pathways | 35 | 0.341 | |||||||
|
||||||||||
| 120 | Signal Transduction | 2590 | 0.341 | |||||||
|
||||||||||
| 121 | IFN-gamma pathway | 31 | 0.341 | |||||||
|
||||||||||
| 122 | Immune response Antigen presentation by MHC class II | 99 | 0.341 | |||||||
|
||||||||||
| 123 | Extracellular vesicles in the crosstalk of cardiac cells | 22 | 0.341 | |||||||
|
||||||||||
| 124 | Cell differentiation - expanded index | 59 | 0.341 | |||||||
|
||||||||||
| 125 | Interleukin-10 signaling | 47 | 0.341 | |||||||
|
||||||||||
| 126 | RAF/MAP kinase cascade | 571 | 0.341 | |||||||
|
||||||||||
| 127 | Toll-like receptor signaling pathway | 285 | 0.341 | |||||||
|
||||||||||
| 128 | Development_Leptin signaling via JAK/STAT and MAPK cascades | 28 | 0.341 | |||||||
|
||||||||||
| 129 | 4-1BB Pathway | 173 | 0.341 | |||||||
|
||||||||||
| 130 | Translation Insulin regulation of translation | 183 | 0.341 | |||||||
|
||||||||||
| 131 | Mammary gland development pathway - Involution (Stage 4 of 4) | 10 | 0.341 | |||||||
|
||||||||||
| 132 | Notch-mediated HES/HEY network | 45 | 0.341 | |||||||
|
||||||||||
| 133 | Infectious disease | 1747 | 0.341 | |||||||
|
||||||||||
| 134 | Innate Immune System | 2025 | 0.341 | |||||||
|
||||||||||
| 135 | Androgen receptor network in prostate cancer | 105 | 0.341 | |||||||
|
||||||||||
| 136 | Intrinsic Pathway for Apoptosis | 55 | 0.341 | |||||||
|
||||||||||
| 137 | Signaling by ALK in cancer | 55 | 0.341 | |||||||
|
||||||||||
| 138 | Development_Thrombopoetin signaling via JAK-STAT pathway | 23 | 0.341 | |||||||
|
||||||||||
| 139 | Colorectal Cancer Metastasis | 165 | 0.341 | |||||||
|
||||||||||
| 140 | Hepatitis C and hepatocellular carcinoma | 55 | 0.341 | |||||||
|
||||||||||
| 141 | Transcription Androgen Receptor nuclear signaling | 98 | 0.341 | |||||||
|
||||||||||
| 142 | G-AlphaQ Signaling | 216 | 0.341 | |||||||
|
||||||||||
| 143 | Physiological and pathological hypertrophy of the heart | 23 | 0.341 | |||||||
|
||||||||||
| 144 | Cytokine production by Th17 cells in CF (Mouse model) | 54 | 0.341 | |||||||
|
||||||||||
| 145 | RNA Polymerase I Promoter Opening | 509 | 0.341 | |||||||
|
||||||||||